Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity

Collaboration focused on undisclosed GPCR targets

Company to receive an upfront and near-term payments, including an equity investment, as well as additional development and commercial milestones, and tiered royalties

(August 14, 2025) by Sarah Sutton.

Boston, MA — August 14, 2025 — Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to rapidly unlock the most challenging G protein-coupled receptors (GPCRs), today announced a collaboration with Eli Lilly and Company (“Lilly”) to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. The collaboration will leverage Superluminal’s cutting-edge, structure-based drug discovery platform, combined with Lilly’s small molecule development and commercialization expertise, to rapidly advance potentially life-changing therapeutics.

“Our collaboration with Lilly is a defining moment for Superluminal, and a testament to the power of our platform to deliver high-quality development candidates against historically intractable GPCR targets,” said Cony D’Cruz, CEO of Superluminal. “Together, we aim to develop nextgeneration medicines that address the urgent and growing global burden of cardiometabolic disease. We are very excited to be embarking on this collaboration just as we begin to advance our internal drug candidate targeting rare genetic forms of obesity and hypothalamic obesity, and we are committed to bringing safe, efficacious, novel treatments to patients affected by these challenging conditions.”